Recently, there is a growing consensus that aspirin, when appropriately used, reduces cardiovascular death in men, ages 45-79, and women ages 55-79 years. The use of aspirin for primary prevention was recommended in the U.S. Preventive Services Task Force Report in 2009 and more recently in the CDC/CMS ‘Million Hearts’ ABCs (aspirin, blood pressure, cholesterol, smoking) campaign. Aspirin use is also recommended in the Healthy People 2020 goals. However, many adults who would benefit, are not taking aspirin.
The State of Minnesota has received a donation to launch a campaign to increase aspirin use. The proposed grant requests funding to evaluate the effectiveness of regular aspirin use. Investigators intend to test new methods to increase appropriate aspirin use. Using a two-arm design, the investigators have defined 24 geographic areas in the state that will form the basis for a group-randomized trial. This design will allow them to distinguish the effects of the intervention methods. The interventions will be evaluated by surveys of the target-age general population at the beginning and as a follow-up. Appropriate aspirin use in that population will be the primary goal and endpoint. Simultaneous surveys of adjacent Upper Midwestern states such as Iowa, North and South Dakota, and Wisconsin will also monitor trends.
A substantial pilot study in a middle sized community in Northern Minnesota allows researchers validate the methods at the community level. This pilot study also demonstrated behavior change. This program, if successful, should result in a generalizable program tested in a real world population setting overall.
This is a randomized, interventional, parallel assignment for the purpose of preventing heart attacks. There is an estimated 10800 participants. The study began in December 2014 and is estimated to be completed by November 2019.
- Healthy men, ages 45-79.
- Healthy women, ages 55-79
- Per USPSTF 2009 recommendations
- History of cardiovascular disease
- Aspirin allergy
- Serious, life-threatening illness
You may participate in this study at the University of Minnesota in Minneapolis, Minnesota, United States, 55455. If you have any questions please contact Russell Luepker at 612-624-6362 or at email@example.com.
This study is sponsored by the University of Minnesota – Clinical and Translational Science Institute.
Clinical TrialsView All
MRI of Myocardial Infarction
Heart failure (HF) affects approximately 5.1 million people in the US and is the cause of 250,000 deaths each year.…
Impact of Daylight on Patients With Acute Myocardial Infarction
Damage from a heart attack usually occurs during the early morning hours. Therefore, the circadian system is…
CLEAR SYNERGY Neutrophil Substudy
CLEAR SYNERGY is an international, randomized placebo controlled trial of the poisonous alkaline colchicine and…
Evaluating Vitamin D Normalization on Cardiovascular-Related Events
This study evaluates whether achieving 25-hydroxyvitamin D, or 25[OH] Vit D (what vitamin D is converted into…
The Impact of Early Follow-up on Readmission Rates in AMI Patients
This study aims to conduct the first randomized, prospective trial to better clear up the association between early…
Testosterone Replacement and Exercise Capacity in Hypogonadal Men
This study examines the effect of testosterone replacement on the ability to exercise for men with functional…